Your Health, We Care
On November 20, 2015, the U.S. Food and Drug Administration (FDA) approved Ninlaro (ixazomib) for the treatment of multiple myeloma.
On September 9, 2015, Cambridge, Massachusetts, USA, and Osaka, Japan, announced that the U.S. Food ···【more】
Recommended：502026-07-01
The U.S. Food and Drug Administration (FDA) approved ixazomib today for use in combination with two ···【more】
Recommended：582026-07-01
On September 9, 2015, Cambridge, Massachusetts, USA, and Osaka, Japan, announced that the U.S. Food and Drug Administration (FDA) had granted priority review status to the New Drug···【more】
Article source：Lucius LaosRelease date：2026-01-07Recommended：50
The U.S. Food and Drug Administration (FDA) approved ixazomib today for use in combination with two other therapies to treat patients with multiple myeloma who have received at lea···【more】
Article source：Lucius LaosRelease date：2026-01-07Recommended：58
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
